Related Experiment Videos
Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment
Y S Cho-Chung1, M Nesterova, S Pepe
1Cellular Biochemistry Section, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
Enhanced expression of the RIa subunit of cAMP-dependent protein kinase type I (PKA-I) has been shown during carcinogenesis, in human cancer cell lines and in primary tumors. We demonstrate that the sequence-specific inhibition of RIa gene expression by antisense oligonucleotides results in the differentiation of leukemia cells and growth arrest of cancer cells of epithelial origin and tumors in mice. The loss of RI by the antisense results in rapid increase in the half-life of the competitor molecule, RII protein, via its stabilization in a holoenzyme complex (PKA-II) that insures depletion of PKA-I and sustained inhibition of tumor growth. RI antisense, which restrains tumor cell growth by turning on the signals for blockade of tumor cell survival, namely blockade of the tyrosine kinase signaling, cell cycle deregulation and apoptosis, provides a single gene-targeting approach to treatment of cancer.
Insights
Targeting the RIa subunit of cAMP-dependent protein kinase type I (PKA-I) with antisense oligonucleotides halts cancer growth. This approach induces leukemia cell differentiation and blocks tumor cell survival signals, offering a novel cancer treatment strategy.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Enhanced expression of the RIa subunit of cAMP-dependent protein kinase type I (PKA-I) is observed in various cancers.
- This subunit plays a role in carcinogenesis and is upregulated in cancer cell lines and primary tumors.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting RIa gene expression in cancer.
- To explore the mechanisms by which RIa inhibition affects cancer cell growth and survival.
Main Methods:
- Utilized sequence-specific antisense oligonucleotides to inhibit RIa gene expression.
- Assessed the effects on leukemia cell differentiation and epithelial cancer cell growth in vitro and in vivo (mouse models).
- Analyzed the impact on PKA-I and PKA-II holoenzyme complexes and protein half-lives.
- Investigated downstream signaling pathways including tyrosine kinase signaling, cell cycle regulation, and apoptosis.
Main Results:
- Sequence-specific inhibition of RIa gene expression led to leukemia cell differentiation and growth arrest in epithelial cancer cells and tumors.
- Antisense-induced loss of RI resulted in stabilization of RII protein within PKA-II holoenzymes, depleting PKA-I.
- Sustained tumor growth inhibition was observed, linked to the blockade of tyrosine kinase signaling, cell cycle deregulation, and induction of apoptosis.
Conclusions:
- Targeting RIa gene expression via antisense oligonucleotides is a viable single gene-targeting strategy for cancer treatment.
- This approach effectively restrains tumor cell growth by activating signals that block tumor cell survival pathways.
- The stabilization of PKA-II and depletion of PKA-I are key mechanisms underlying the observed anti-cancer effects.